Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs

Journal of Pharmaceutical Sciences

Volumn 86, Issue 5, 1997, Pages 584-590

  Lave, Th ^a   Dupin, S ^a   Schmitt, C ^a   Chou, R C ^a   Jaeck, D ^a,b   Coassolo, Ph ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CAFFEINE; MIBEFRADIL; MIDAZOLAM; MOFAROTENE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENAZONE; PROPRANOLOL; RO 24 6173; THEOPHYLLINE; TOLCAPONE; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; LIVER CLEARANCE; MALE; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; SPECIES DIFFERENCE; SWINE;

EID: 0030918716     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js960440h     Document Type: Article

References (32)

1. Charnick, S. B.; Kawai, R.; Nedelman, J. R; Lemaire, M.; Niederberger, W.; Sato, H. Physiologically based pharmacokinetic modeling as a tool for drug development. J. Pharmacokinet. Biopharm. 1995, 23, 217-229.
2. Mordenti, J. Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob. Agents Chemother. 1985, 27, 887-91.
3. Mordenti, J. Man versus beast: Pharmacokinetic scaling in mammals. J. Pharm. Sci. 1986, 75, 1028-40.
4. Efthymiopoulos, C.; Battaglia, R.; Strolin-Benedetti, M. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. J. Antimicrob. Chemother. 1991, 27, 517-26.
5. Sawada, Y.; Hanano, M.; Sugiyama, Y.; Iga, T. Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm. 1984, 12, 241-61.
6. Swabb, E. A.; Bonner, D. P. Prediction of aztreonam pharmacokinetics in humans based on data from animals. J. Pharmacokinet. Biopharm. 1983, 11, 215-23.
7. Mordenti, J.; Chen, S. A.; Moore, J. A.; Ferraiolo, B. L.; Green, J. D. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 1991, 8, 1351-9.
8. Brocks, D. R.; Freed, M. I.; Martin, D. E.; Sellers, T. S.; Mehdi, N.; Citerone, D. R.; Boppana, V.; Levitt, B.; Davies, B. E.; Nemunaitis, J.; et al. Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharmaceut. Res. 1996, 13, 794-797.
9. Boxenbaum, B.; D'Souza, R. W. Interspecies Pharmacokinetic Scaling, Biological Design and Neoteny. In Advances in Drug Research; Testa, B., Ed.; Academic Press Limited: London, 1990; pp 139-196.
10. McNamara, P. J. Interspecies scaling in pharmacokinetics. In Interspecies scaling in pharmacokinetics; Welling, P. G. Tse, F. L. S., Dighe, S. V., Eds.; Marcel Dekker: New York, 1991; pp 267-300.
11. Mahmood, I.; Balian, J. D. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci. 1996, 85, 411-414.
12. Campbell, D. B. Can allometric interspecies scaling be used to predict human kinetics. Drug Inf. J. 1994, 28, 235-245.
13. Boxenbaum, H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. 1984, 15, 1071-121.
14. Lave, T.; Coassolo, P.; Ubeaud, G.; Brandt, R.; Schmitt, C.; Dupin, S.; Jaeck, D.; Chou, R. C. Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharm. Res. 1996, 13, 97-101.
15. Lave, T.; Schmitt-Hoffmann, A. H.; Coassolo, P.; Ubeaud, G.; Vallès, B.; Ba, B.; Brandt, R.; Chou, R. C. A new extrapolation method from animal to man; application to a metabolized compound, mofarotene. Life Sci. 1995, 56, 473-478.
16. Lave, T.; Dupin, S.; Schmitt, M.; Kapps, M.; Meyer, J.; Morgenroth, B.; Chou, R. C.; Jaeck, D.; Coassolo, P. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 1996, 26, 839-851.
17. Seglen, P. O. Preparation of isolated rat liver cells. Methods Cell. Biol. 1976, 13, 29-83.
18. Seddon, T.; Michelle, I.; Chenery, R. J. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem. Pharmacol. 1989, 38, 1657-1665.
19. Ubeaud, G.; Schmitt, C.; Jaeck, D.; Lavé, T.; Coassolo, P. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995, 25, 1381-1390.
20. Zomorodi, K.; Carlile, D. J.; Houston, J. B. Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 1995, 25, 907-916.
21. Houston, J. B. Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol. In Vitro 1994, 8, 507-512.
22. Houston, J. B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994, 47, 1469-1479.
23. Chiou, W. L.; Hsu, F. H. Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharmaceut. Res. 1988, 5, 668-72.
24. Boxenbaum, H.; Fertig, J. B. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur. J. Drug Metab. Pharmacokinet. 1984, 9, 177-83.
25. Bonati, M.; Latini, R.; Tognoni, G.; Young, J. F.; Garattini, S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab. Rev. 1984, 15, 1355-83.
26. Mandema, J. W.; Tuk, B.; van-Steveninck, A. L.; Breimer, D. D.; Cohen, A. F.; Danhof, M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 1992, 51, 715-28.
27. Hall, R. I.; Szlam, F.; Hug, C., Jr. Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. J. Pharmacokinet. Biopharm. 1988, 16, 251-62.
28. Ochs, H. R.; Greenblatt, D. J.; Eichelkraut, W.; Bakker, C.; Göbel, R.; Hahn, N. Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. J. Pharmacol. Exp. Ther. 1987, 243, 852-856.
29. Smith, M. T.; Eadie, M. J.; Brophy, T. O. The pharmacokinetics of midazolam in man. Eur. J. Clin. Pharmacol. 1981, 19,
30. Evans, G. H.; Nies, A. S.; Shand, D. G. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J. Pharmacol. Exp. Ther. 1973, 186, 114-122.
31. Vincon, G.; Ploux, D.; Pehourcq, F.; Albin, H. J. Pharmacol. 1983, 14, 47-55.
32. Gaspari, F.; Bonati, M. Interspecies metabolism and pharmacokinetic scaling of theophylline disposition. Drug Metab. Rev. 1990, 22, 179-207.